KEYNOTE-427 updates: First-line pembrolizumab monotherapy in patients with advanced clear cell renal cell carcinoma

Bookmark and Share
Published: 14 Jul 2020
Views: 161
Rating:
Save
Prof Scott Tykodi - University of Washington, Seattle, USA

Prof Scott Tykodi speaks to ecancer in an online interview for the virtual ASCO 2020 meeting.

He presents the updated results from KEYNOTE-427, which is an open-label, single-arm, phase II study investigating the use of first-line pembrolizumab monotherapy in patients with advanced clear cell renal cell carcinoma (ccRCC).

Prof Tykodi concludes that first-line pembrolizumab monotherapy shows promising anti-tumour activity in this patient population.